Work

Comparative cost-effectiveness of HPV mRNA and DNA testing for anal cancer screening in MSM living with HIV: a model-based study

Year: 2026
Type: article
Abstract: Anal cancer incidence is increasing among men who have sex with men (MSM) living with HIV, driven by persistent high-risk (HR) HPV infection. HPV mRNA testing may offer higher specificity for detecting high-grade squamous intraepithelial lesions (HSIL) than cytology or HPV DNA testing, with potential economic implications. We evaluated the cost-effectiveness of screening strategies combining HPV biomarkers and post-high-resolution anoscopy (HRA) management. A Markov model simulated a cohort of MSM living with HIV to assess 45 screening strategies varying by algorithm (cytology, co-testing, HPV reflex), HPV assay (DNA-hybridization, DNA-PCR, mRNA), and post-HRA management (follow-up, infrared coagulation [IRC], trichloroacetic acid [TCA]). Outcomes included HSIL and anal cancer cases, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Strategies involving treatment reduced anal cancer incidence by 43–69% compared with no screening, with greater reductions for co-testing. Cytology was the most cost-effective option at €25 per test. At €6, co-testing became competitive, particularly with HR-HPV assays—DNA-hybridization (€13,203/QALY) and mRNA (€14,482/QALY). All optimal strategies included TCA. Anal cancer screening in MSM living with HIV is effective and cost-effective. Co-testing with cytology and HR-HPV assays—whether DNA or mRNA—combined with post-HRA treatment provided the greatest health benefits, while its cost-effectiveness depended strongly on HPV test cost and became favorable at lower HPV test costs. HPV mRNA-based approaches provided a comparable and viable alternative to HPV DNA.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7136136663
FWCI:
Cites: 24
Cited by:
Related to: 10